Cardax

Cardax OCF Margin

The Operating Cash Flow Margin of Cardax (CDXI) as of Oct 19, 2026 is -332.39 %. In the previous year, Operating Cash Flow Margin was -495.47 % — a change of -32.91% (higher).

OCF Margin

-332.39 %

YoY

-32.91%

Last updated:

Operating Cash Flow Margin of Cardax is 2020 -332.39 % . Operating Cash Flow Margin of Cardax was 2019 -495.47 % . It decreases by -32.91% higher compared to the previous year.

The Cardax OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2016
-3,560.34 USD
Jan 1, 2017
-340.91 USD
Jan 1, 2018
-211.83 USD
Jan 1, 2019
-495.47 USD
Jan 1, 2020
-332.39 USD
The Cardax OCF Margin history
YEAROCF MarginYoY
-332.39 %-32.91%
-495.47 %+133.90%
-211.83 %-37.86%
-340.91 %-90.42%
-3,560.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

Operating Cash Flow Margin of Cardax is -332.39 % in 2020.

Operating Cash Flow Margin of Cardax changed from -495.47 % to -332.39 %, representing a -32.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Cardax since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Cardax with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cardax

All Key Metrics — Cardax